Ganaxolone for irritability in children with autism
Part of Mental health clinical trials.
This study tests whether a medicine called ganaxolone can reduce irritability (frequent tantrums or aggression) in children with autism. The child will take the drug or a placebo (a dummy pill) for a period, and researchers will monitor behavior and brain activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 5 and 17 years old at the start of the study
- Must have a confirmed autism diagnosis (based on DSM-5 criteria)
- Must be medically stable, with no serious heart or seizure problems
- Medications must be stable for at least 2 weeks before starting (4 weeks if taking fluoxetine)
- Must have a caregiver who can answer questions in English and reliably report the child's behavior
- Family must be able to travel to Stanford University (within 150 miles) for study visits, including EEG and MRI scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether N-acetylcysteine, a medicine taken by mouth, can improve autism-related restricted and repetitive behaviors in children. It looks at children who are showing at least moderate severity in these behaviors and may involve brain testing for safety reasons.
This Phase 2 study tests whether a single dose of N-acetylcysteine can improve “restricted and repetitive behaviors” in children with autism. It’s meant for kids who are stable and still in early puberty stages.
This Phase 2 study tests zolpidem (a sleep medicine) to help children with autism sleep better. It will check sleep changes using sleep testing and to confirm zolpidem is safe for this age group.
This trial tests whether buspirone, a medication that helps with anxiety, can reduce anxiety in children and teens with autism. It is a 12-week study where participants receive buspirone or a placebo (a pill with no medicine) to see if it improves anxiety symptoms.
This trial tests a new cell-based treatment (called VGN-Ex05e) for young people with autism who have severe self-injury or aggression that hasn't improved with standard treatments. The treatment is given as a one-time injection into a specific area of the brain (nucleus accumbens) to help calm these behaviors.
This Phase 2 study tests CBDV, a form of cannabis-based medicine, compared with placebo (dummy medicine) in children with autism who have significant irritability and social challenges. It aims to see whether CBDV can improve behavior and overall symptom severity safely over the study period.
Hear when a new Autism in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.